Overall, these results indicate that pharmacological blockade of the IGFBP3/TMEM219 signaling/binding with ecto-TMEM219 in vivo ameliorates signs and symptoms of acute colitis and preserves intestinal immune homeostasis. The gene discussed is IGFBP3; the disease is colitis.